Effect of low dose methotrexate as an add-on therapy in patients with palindromic rheumatism unresponsive to hydroxychloroquine: An observational study

Padhan, Prasanta; Thakur, Bhaskar

doi:10.5152/eurjrheum.2021.20062

Cited by 5 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 The number of attacks decreased to 1-2 per months in 53% of patients at 3 months. 7 However, the number of attacks were 0 in 73% of patient at 6 months. In the remaining cases, the number of attacks was 1-2 per month.…”

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 93%

“…7 The median duration of attacks at 3 and 6 months decreased from 36 hours to 6 and 0 hours, respectively. 7 No patient developed RA during the follow-up period. 6 In comparison with the study by of MTX in our study were comparable to the Padhan et al 7 study.…”

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 94%

“…23 Padhan et al reported results of treatment with MTX in 15 patients with RF and or ACPA positive PR who had active disease despite treatment with HCQ 5 mg/kg/d ± low-dose prednisolone for at least 6 months. 7 They defined active disease as ≥2 attacks of arthritis per month. MTX was used with doses 14.5 ± 4.7 mg/wk as add-on therapy with HCQ.…”

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 99%

“…6 Recently, Padhan et al reported the efficacy of methotrexate (MTX) in the treatment of 15 patients with seropositive PR with inadequate response to HCQ. 7 Duration of treatment with MTX was 6 months. 7 The present study was performed to report the results of PR treatment with MTX with a larger sample size and longer follow-up time.…”

mentioning

confidence: 99%

“…7 Duration of treatment with MTX was 6 months. 7 The present study was performed to report the results of PR treatment with MTX with a larger sample size and longer follow-up time.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Long‐term outcome of patients with palindromic rheumatism treated with methotrexate

et al. 2022

View full text Add to dashboard Cite

Objective Palindromic rheumatism (PR) is characterized by self‐resolving and short duration attacks of arthritis/periarthritis. The present study was performed to report the results of PR treatment with methotrexate (MTX). Methods We reviewed the charts of 152 patients with diagnosis of PR. Inclusion criteria were diagnosis of PR according to the criteria of Weismann, age ≥16, active disease and treatment with MTX for at least 6 months. Disease outcome was assessed by reaching remission and prevention of disease evolution to chronic arthritis. Remission was defined as stopping the attacks for 12 weeks and prednisolone dose ≤5 mg/d. MTX treatment failure was defined as failure to achieve remission, the need to add other disease‐modifying antirheumatic drugs and disease progression to chronic arthritis. Results Fifty‐nine patients were included in the study. Median duration of follow‐up was 43 months. Attacks were controlled in 89.8% of patients. In 80% of the patients remission occurred during 12 months after starting treatment with MTX. Treatment failed in 20.3% of patients. Wrist joint involvement and positive rheumatoid factor (RF) were significantly more common in the MTX treatment‐failed group. In RF positive patients evolution to rheumatoid arthritis was more common than in RF negative patients. No significant differences were observed in remission rate and evolution to rheumatoid arthritis in anticitrullinated C peptide positive and negative patients. Conclusions The present study, demonstrated the efficacy of MTX in controlling PR in seropositive and seronegative patients over a median of 43 months of treatment.

show abstract

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 93%

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 94%

Section: Ta B L E 2 Outcomes Of Treatment With Mtx In 59 Patients Wit...mentioning

confidence: 99%

mentioning

confidence: 99%

“…7 Duration of treatment with MTX was 6 months. 7 The present study was performed to report the results of PR treatment with MTX with a larger sample size and longer follow-up time.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long‐term outcome of patients with palindromic rheumatism treated with methotrexate

et al. 2022

View full text Add to dashboard Cite

show abstract

Iguratimod efficacy in palindromic rheumatism treatment

Yuan

Luo

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background As a new immunomodulator for rheumatoid arthritis, iguratimod (IGU) also has therapeutic potential in other immune diseases. In this study, we determined the effects of IGU on disease control in patients with palindromic rheumatism (PR). Methods Patients with PR were divided into Control group (Ctrl group) and an IGU treatment (IGU group) groups. Drug efficacy was evaluated according to the frequency of PR attacks (monthly), the visual analog scale (VAS) score of patient pain, and clinical symptoms. Results The drug positivity and disease control rates of the IGU group (100.00% and 90.91%, respectively) were significantly higher than those of the Ctrl group (61.11% and 5.56%; p = .002 and p < .001, respectively). The median number of PR flares and the VAS score of patients in the Ctrl group decreased from 3.00 (1.00–15.00) to 0.83 (0.00–12.00) and from 5 (4–6) to 4 (1–6), respectively. In the IGU group, the median number of PR attacks decreased from 4.50 (2.00–15.00) to 0.00 (0.00–0.33), and the VAS score decreased from 5 (4–6) to 0 (0–2). The IGU group exhibited a significant reduction in PR flare frequency and improvement in the VAS value (p < .001 and p < .001, respectively). Conclusion Our study is the first to describe the efficacy of IGU in PR treatment. IGU can significantly reduce the number of PR flares and improve the clinical symptoms of patients with PR.

show abstract

Early and advanced stages in palindromic rheumatism patients: Test characteristics of three classification criteria and discrimination potential

Myong-hak

Po-hum

Song-phil³

et al. 2022

The Egyptian Rheumatologist

View full text Add to dashboard Cite

Effect of low dose methotrexate as an add-on therapy in patients with palindromic rheumatism unresponsive to hydroxychloroquine: An observational study

Cited by 5 publications

References 12 publications

Long‐term outcome of patients with palindromic rheumatism treated with methotrexate

Long‐term outcome of patients with palindromic rheumatism treated with methotrexate

Iguratimod efficacy in palindromic rheumatism treatment

Early and advanced stages in palindromic rheumatism patients: Test characteristics of three classification criteria and discrimination potential

Contact Info

Product

Resources

About